Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/178497
Title: | Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients |
Author: | Fernández-Barat, Laia Motos, Anna Panigada, Mauro Álvarez Lerma, Francisco Viña, Lucía López Aladid, Rubén Ceccato, Adrian Bassi, Gianluigi Li Nicolau, David P. López, Yuly Muñoz López, Laura Guerrero Latorre, Laura Soy Muner, Dolors Israel, Trinidad Castro, Pedro Torres Martí, Antoni |
Keywords: | Infeccions respiratòries Malalties de l'aparell respiratori Microbiologia mèdica Virus Respiratory infections Respiratory diseases Medical microbiology Viruses |
Issue Date: | 2019 |
Publisher: | BioMed Central |
Abstract: | Purpose: To compare the efficacy of systemic treatment with linezolid (LNZ) versus vancomycin (VAN) on methicillinresistant Staphylococcus aureus (MRSA) burden and eradication in endotracheal tube (ETT) biofilm and ETT cuff from orotracheally intubated patients with MRSA respiratory infection. Methods: Prospective observational clinical study was carried out at four European tertiary hospitals. Plasma and endotracheal aspirate (ETA) levels of LNZ and VAN were determined 72 h after treatment initiation through high-performance liquid chromatography or bioassay. LNZ or VAN concentration in the ETT biofilm and MRSA burden and eradication was determined upon extubation. The minimum inhibitory concentration (MIC) for LNZ and VAN was assessed by E-test strips (Biomerieux®). Scanning electron microscopy images were obtained, and ETT biofilm thickness was compared between groups. Results: Twenty-five patients, 15 treated with LNZ and 10 with VAN, were included in the study. LNZ presented a significantly higher concentration (μg/mL) than VAN in ETT biofilm (72.8 [1.3-127.1] vs 0.4 [0.4-1.3], p < 0.001), although both drugs achieved therapeutic plasma levels 72 h after treatment initiation. Systemic treatment with LNZ achieved lower ETT cuff MRSA burdens than systemic treatment with VAN. Indeed, LNZ increased the MRSA eradication rate in ETT cuff compared with VAN (LNZ 75%, VAN 20%, p = 0.031). Conclusions: In ICU patients with MRSA respiratory infection intubated for long periods, systemic treatment with LNZ obtains a greater beneficial effect than VAN in limiting MRSA burden in ETT cuff. Keywords: E |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s13054-019-2523-5 |
It is part of: | Critical Care, 2019, vol. 23, p. 251 |
URI: | http://hdl.handle.net/2445/178497 |
Related resource: | https://doi.org/10.1186/s13054-019-2523-5 |
ISSN: | 1364-8535 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
691517.pdf | 1 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License